In-Vitro Release and Pharmacokinetics of Anti-tubercle Drug Ethionamide in Healthy Male Subjects

Abstract

The aim of study was to assess the pharmacokinetics of ethionamide in the local population of healthy human sub- jects. Serum samples were taken from each of the selected subject at different time intervals. These samples were analyzed by using High Performance Liquid Chromatog- raphy consisting of reverse phase C18 column, UV detec- tor set at 291nm. The mobile phase was consisted of 0.02 M disodium hydrogen phosphate and acetonitrile (75:25) and delivered at a rate of 1.5ml/min. The value of Cmax was found to be 1.941 ± 1.487 µg/ml (mean ± SEM) and Tmax was 1.75 ± 1.487 hours (mean ± SEM). The area un- der the curve (AUC) was 8.745 ± 0.536 (mean ± SEM). The elimination half life (t½ ) was found out as 1.995 ± 1.157 hours (mean ± SEM). The total body clearance (Cl) was determined as 32.591 ± 0.298 ml/hr/kg (mean ± SEM). It was concluded that ethionamide (Ethomid® Schazoo- Lahore, Pakistan) found in consistent with the values re- ported in the available literature. The study will be ben- eficial and valuable in designing dosage regimen for the patients on ethionamide therapy and can be utilized as guideline in accessing the bioavailability and pharmaco- kinetics parameters in clinical situations.